What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...
Автори: | Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
2010
|
Схожі ресурси
Схожі ресурси
-
Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
за авторством: Testa, L, та інші
Опубліковано: (2010) -
Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
за авторством: L. Testa, та інші
Опубліковано: (2010-01-01) -
Use of prasugrel in patients with clopidogrel hypersensitivity
за авторством: Aparna Joshi, та інші
Опубліковано: (2022-01-01) -
Interaction between statins and clopidogrel: is there anything clinically relevant?
за авторством: Bhindi, R, та інші
Опубліковано: (2008) -
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
за авторством: Satoshi Niijima, та інші
Опубліковано: (2018-03-01)